Tirzepatide and asthma: what people with a respiratory condition need to know

Why your prescriber needs to know about your asthma

A question our prescribers hear most weeks, in some form, is: "I have a condition alongside obesity — does it rule me out?" With asthma, the honest answer is that it rarely rules a person out, but it absolutely needs to be declared. Tirzepatide is a dual GIP and GLP-1 receptor agonist licensed in the UK for weight management in adults with a BMI of 30 or above, or 27 and above alongside at least one weight-related health condition. Asthma can qualify as that weight-related condition in some clinical contexts, though the prescriber makes that call based on the individual.

The reason full disclosure matters is practical. Tirzepatide slows gastric emptying, and in rare cases this can be associated with acid reflux. For people whose asthma is worsened by reflux (a pattern that is more common than many realise) starting on the lowest dose and titrating slowly gives the body time to adjust. Your prescriber will also want to know which inhalers you use, how well your asthma is currently controlled, and whether you have any other respiratory or cardiovascular conditions that might affect the benefit-risk balance.

The UK SmPC for tirzepatide, published on the electronic Medicines Compendium, does not list asthma as a contraindication. What it does require is that treatment starts at 2.5 mg and is titrated under clinical supervision. That structure exists for tolerability reasons, and it gives both the patient and the prescriber useful early information about how the medicine is being tolerated.

What the evidence says about obesity, asthma and weight loss

The relationship between obesity and asthma is well-established. Excess weight around the chest and abdomen restricts the space the lungs have to expand, raises inflammation markers throughout the body, and can worsen airway reactivity. NHS guidance on weight management consistently notes that losing clinically meaningful weight can reduce asthma symptom frequency and severity, and in some people reduces reliever inhaler use over time.

Tirzepatide's clinical programme (spanning the SURMOUNT trials involving thousands of adults with obesity) demonstrated average weight reductions of around 20% at the highest dose over 72 weeks. While the SURMOUNT trials did not specifically measure asthma outcomes as primary endpoints, the broader evidence base for weight loss and respiratory improvement is substantial. Research published through the NIHR Evidence platform supports the view that intentional weight loss through any effective intervention tends to carry respiratory benefits for people with obesity-related asthma.

None of that makes tirzepatide a treatment for asthma. Its licence covers weight management alongside lifestyle changes. The potential respiratory improvement is a downstream effect of losing weight, not a direct pharmacological action of the medicine itself. Keeping that distinction clear matters, because it also means people should not adjust or stop their inhalers on the basis of starting tirzepatide without discussing it first with the clinician managing their asthma.

The practical things worth considering before you decide

If you are weighing up whether tirzepatide is the right step, a few practical considerations are worth thinking through before a consultation. First, asthma control matters. Starting a new medicine during a period of poor asthma control (frequent rescue inhaler use, a recent course of oral steroids, a recent hospital admission) adds variables that make it harder to tell what is causing any new symptoms. Ideally, your asthma should be reasonably stable before you begin.

Second, steroid inhalers used at high doses over long periods can contribute to weight gain in some people, which in turn worsens asthma. Some people find that as weight falls, their asthma management becomes easier and their steroid burden reduces. That is a conversation for the clinician managing your asthma, but it is worth flagging at a weight-management consultation too. You can read more about taking Mounjaro with asthma including how the two conditions interact in practice.

Third, cost is a real consideration. Private treatment is priced per month and varies by dose; if you want to understand what transparent private pricing looks like compared with what is typically quoted elsewhere, the cost context page sets out what UK market pricing typically includes and excludes. For some people, the NHS route via a GP is now opening up, eligibility is phased, and criteria are strict, but it is worth checking whether you qualify. Details of how the phased rollout works are on our weight loss overview page.

People with other conditions alongside asthma may find the pages on tirzepatide and PCOS or tirzepatide and liver conditions useful for understanding how comorbidities are handled in clinical assessment. Every case is individual, and a prescriber's job is to weigh the evidence for your specific situation, not to apply a blanket rule.

When to speak to a clinician rather than reading further

Some situations call for a conversation rather than more research. If your asthma is severe or brittle, if you are on oral corticosteroids long-term, if you have a history of hospitalisation for respiratory episodes, or if you have been told your asthma is difficult to control, those are the kinds of details that can only be properly assessed in a clinical review. Our dedicated page covering Mounjaro and asthma goes into the clinical detail of how these situations are assessed and what prescribers typically look for. The same applies if you have any concern about how a side effect might interact with your breathing.

The common gastrointestinal side effects of tirzepatide (which can include nausea, reflux, and occasional vomiting during dose escalation) are not typically dangerous for people with well-controlled asthma, but they can be uncomfortable, and in anyone whose asthma is reflux-triggered, they are worth flagging explicitly. Anyone who develops a new wheeze, chest tightness, or unexpected breathing difficulty after starting tirzepatide should contact their GP or asthma nurse promptly, and should not assume the symptom is simply a gastrointestinal effect. The MHRA Yellow Card scheme exists for reporting any unexpected side effect from a licensed medicine, and patients can use it directly.

If you would like a prescriber to review your full health picture, our clinical team carries out same-day personal reviews, a real clinician reads your consultation, not software. You can also browse our frequently asked questions if you have general queries before starting. When you are ready to take the next step, speaking to our prescribers is the right place to begin.